Efficacy of Vyoshadi Guggulu and Shadushana Churna in the management of subclinical hypothyroidism: An open labelled randomized comparative pilot clinical trial

Ayu Pub Date : 2020-07-01 DOI:10.4103/ayu.ayu_359_20
V. B. Sharma, B. Padhar, H. Meena, S. Mathur
{"title":"Efficacy of Vyoshadi Guggulu and Shadushana Churna in the management of subclinical hypothyroidism: An open labelled randomized comparative pilot clinical trial","authors":"V. B. Sharma, B. Padhar, H. Meena, S. Mathur","doi":"10.4103/ayu.ayu_359_20","DOIUrl":null,"url":null,"abstract":"Background: Subclinical hypothyroidism (SCH) is defined as a mildly reduced function of the thyroid gland having elevated serum thyroid-stimulating hormone (TSH) level and normal concentrations of free tri-iodothyronine (FT3), free tetra-iodothyronine (FT4), T3 and T4. It occurs due to “Agnimandya” (low metabolic activity) at the systemic and cellular level. Vyoshadi Guggulu and Shadushana Churna having its effect on Agni (a root cause of SCH) are expected to prevent overt hypothyroidism and revert subclinical stage to euthyroid. Aim: This study was planned to evaluate and compare the efficacy of Vyoshadi Guggulu and Shadushana Churna in the management of Dhatvagnimandya with special reference to sub-clinical hypothyroidism (SCH). Materials and methods: Patients having serum TSH levels between 5 and 10 mlU/L and normal T3 and T4 values were diagnosed as SCH. A total of 30 patients were registered and randomly divided into two groups. In group A, patients were treated with Vyoshadi Guggulu (6 g), while in group B with Shadushana Churna (3 g) twice a day after lunch and dinner for 60 days. The assessment was done through changes in baseline and after treatment values of serum TSH level. Outcomes of the trial were analyzed using SigmaStat 4.0 version (trial) software. Student's paired t-test was used for within-group assessment, while unpaired t-test was used for intergroup comparison of the normally distributed parametric data. Observations and Results: Ten patients in group A and 11 in group B could complete the course of treatment. The findings revealed that therapy in group A and B showed decrease of 16.61% (P = 0.0494) and 26.29% (P = 0.0140) in serum TSH, respectively, 1.80% (P = 0.025) and 1.36% (P = 0.019) decrease in body mass index (BMI), respectively. The decrease in TSH and BMI was statistically significant in each group. In comparison, the decrease in serum TSH (P = 0.384) and BMI (P = 0.677) was statistically insignificant. Conclusions: Vyoshadi Guggulu and Shadushana Churna are statistically equally effective to reduce serum TSH and BMI in the management of SCH.","PeriodicalId":8720,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ayu","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ayu.ayu_359_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Subclinical hypothyroidism (SCH) is defined as a mildly reduced function of the thyroid gland having elevated serum thyroid-stimulating hormone (TSH) level and normal concentrations of free tri-iodothyronine (FT3), free tetra-iodothyronine (FT4), T3 and T4. It occurs due to “Agnimandya” (low metabolic activity) at the systemic and cellular level. Vyoshadi Guggulu and Shadushana Churna having its effect on Agni (a root cause of SCH) are expected to prevent overt hypothyroidism and revert subclinical stage to euthyroid. Aim: This study was planned to evaluate and compare the efficacy of Vyoshadi Guggulu and Shadushana Churna in the management of Dhatvagnimandya with special reference to sub-clinical hypothyroidism (SCH). Materials and methods: Patients having serum TSH levels between 5 and 10 mlU/L and normal T3 and T4 values were diagnosed as SCH. A total of 30 patients were registered and randomly divided into two groups. In group A, patients were treated with Vyoshadi Guggulu (6 g), while in group B with Shadushana Churna (3 g) twice a day after lunch and dinner for 60 days. The assessment was done through changes in baseline and after treatment values of serum TSH level. Outcomes of the trial were analyzed using SigmaStat 4.0 version (trial) software. Student's paired t-test was used for within-group assessment, while unpaired t-test was used for intergroup comparison of the normally distributed parametric data. Observations and Results: Ten patients in group A and 11 in group B could complete the course of treatment. The findings revealed that therapy in group A and B showed decrease of 16.61% (P = 0.0494) and 26.29% (P = 0.0140) in serum TSH, respectively, 1.80% (P = 0.025) and 1.36% (P = 0.019) decrease in body mass index (BMI), respectively. The decrease in TSH and BMI was statistically significant in each group. In comparison, the decrease in serum TSH (P = 0.384) and BMI (P = 0.677) was statistically insignificant. Conclusions: Vyoshadi Guggulu and Shadushana Churna are statistically equally effective to reduce serum TSH and BMI in the management of SCH.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Vyoshadi Guggulu和Shadushana Churna治疗亚临床甲状腺功能减退的疗效:一项开放标记随机对照临床试验
背景:亚临床甲状腺功能减退症(SCH)被定义为甲状腺功能轻度降低,血清促甲状腺激素(TSH)水平升高,游离三碘甲状腺原氨酸(FT3)、游离四碘甲状腺原氨酸(FT4)、T3和T4浓度正常。它的发生是由于“Agnimandya”(低代谢活动)在系统和细胞水平。Vyoshadi Guggulu和Shadushana Churna对Agni (SCH的根本原因)有作用,有望预防明显的甲状腺功能减退,并将亚临床阶段恢复到甲状腺功能正常。目的:评价和比较Vyoshadi Guggulu和Shadushana Churna治疗亚临床甲状腺功能减退症(SCH)的疗效。材料与方法:将血清TSH水平在5 ~ 10 mlU/L之间,T3、T4值正常的患者诊断为SCH。30例患者随机分为两组。A组患者服用Vyoshadi Guggulu (6 g), B组患者服用Shadushana Churna (3 g),每天两次,午餐和晚餐后服用,连续60天。通过基线和治疗后血清TSH水平的变化进行评估。使用SigmaStat 4.0版本(试用版)软件对试验结果进行分析。组内评价采用学生配对t检验,组间比较采用非配对t检验。观察与结果:A组10例,B组11例均能完成疗程。结果显示,A组和B组血清TSH分别下降16.61% (P = 0.0494)和26.29% (P = 0.0140),体重指数(BMI)分别下降1.80% (P = 0.025)和1.36% (P = 0.019)。各组TSH和BMI下降均有统计学意义。相比之下,血清TSH (P = 0.384)和BMI (P = 0.677)的下降无统计学意义。结论:Vyoshadi Guggulu和Shadushana Churna在降低血清TSH和BMI方面具有统计学上相同的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ayu
Ayu
自引率
0.00%
发文量
0
期刊最新文献
A systematic review in health care: Need and significance. Ayurveda fundamentals and science - A perspective. Management of Mutrashmari (urolithiasis) with Palasha Kshara and Ashmarihara Kwatha: An open-labelled placebo-controlled clinical trial. A lexical review on Vishaghna Dravyas of Kaideva Nighantu. Antioxidant content and activity of stem and leaf extracts of Gouania longipetala Hemsl. (Rhamnaceae).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1